Tag Archive for: Novo Holdings

An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022

Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]

Novo Nordisk Foundation: Major investment for developing Denmark’s first fully functional quantum computer

Denmark’s first fully functional generally applicable quantum computer will be available in 2034. This is the objective of the ambitious Novo Nordisk Foundation Quantum Computing Programme that is being launched in collaboration with the University of Copenhagen. Quantum computers will help in developing new medicine and provide new insight into climate change and the green […]

Novo Ventures is ready for steady deployment of funds amid IPO lull

Novo Ventures senior partner, Naveed Siddiqi, discussed the opportunity in a slumbering IPO market to raise larger funding rounds, in an interview with Unquote.

How Early-stage VCs are Adjusting in a Bear Market

As part of a panel session, hosted by Stephen Hansen, at the Anglonordic Life Science conference on 5 May, Optimum’s clients explored the latest dynamics of syndicate building for early-stage VCs.

Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics

Financing co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch Proceeds will be used to develop next-generation T-cell receptor-based therapies for cancer treatment TCR therapy pioneer and industry veteran Dr Bent Jakobsen appointed as Chairman of the Board Basel, Switzerland, May 3, 2022. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel […]